01547nam a2200385 i 4500001001300000003000300013005001700016008004100033040002500074041000800099042000800107043001200115050001600127074000900143086002100152088002300173110004300196240006900239245012200308264007100430300002300501336002600524337002800550338002700578500002400605500003600629500003100665500002100696500002600717500002500743610007000768650005600838655003100894776023600925ocn951215147BD20161116131536.0160606s2016    dcu      l   f000 0 eng c  aPUCPRbengerdacGPO  aspa  apcc  an-us---  aKF 50b.U56  a05750 aAE 2.110:114-146  aPublic Law 114-1461 aUnited States,eenacting jurisdiction.10aAdding Zika Virus to the FDA Priority Review Voucher Program Act13aAn Act to Expand the Tropical Disease Product Priority Review Voucher Program to Encourage Treatments for Zika Virus. 1a[Washington, D.C.] :b[U.S. Government Publishing Office],c[2016]  a[1] leaf ;c24 cm.  atextbtxt2rdacontent  aunmediatedbn2rdamedia  avolumebnc2rdacarrier  aTitle from caption.  aShipping list no.: 2016-0275-P.  a"Apr. 19, 2016 (S. 2512)."  a"130 Stat. 357."  a"Public Law 114-146."  aCRDP Project record.10aUnited States.bFood and Drug AdministrationxRules and practice. 0aVirus diseasesxLaw and legislationzUnited States. 7aStatutes and codes.2lcgft08iOnline version:aUnited States.sAdding Zika Virus to the FDA Priority Review Voucher Program Act.tAct to Expand the Tropical Disease Product Priority Review Voucher Program to Encourage Treatments for Zika Virusw(OCoLC)949906329